See the DrugPatentWatch profile for cosentyx

Cosentyx, a medication used to treat several conditions including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, is typically administered through injection [1]. The treatment length for Cosentyx can vary depending on the specific condition being treated, the patient's response to the medication, and the guidance of the prescribing physician.

For plaque psoriasis, Cosentyx is often used long-term to manage symptoms. A clinical trial studying the efficacy of Cosentyx for plaque psoriasis found that after 52 weeks of treatment, 75% of patients on Cosentyx had a 75% or greater reduction in their psoriasis area and severity index (PASI) score [2].

For psoriatic arthritis, Cosentyx has been shown to improve symptoms and physical function over the course of 24 weeks [3]. In a clinical trial, 52% of patients receiving Cosentyx achieved an ACR20 response (a measure of improvement in arthritis symptoms) at week 24, compared to 33% of those receiving a placebo [3].

For ankylosing spondylitis, Cosentyx has been shown to improve symptoms and physical function over the course of 12 weeks [4]. In a clinical trial, 56% of patients receiving Cosentyx achieved an ASAS20 response (a measure of improvement in ankylosing spondylitis symptoms) at week 12, compared to 29% of those receiving a placebo [4].

It is important to note that individual treatment plans may vary, and patients should follow the guidance of their prescribing physician regarding the length of Cosentyx treatment.

Sources:

1. Cosentyx (secukinumab) [Internet]. Drugs.com. [cited 2023 Mar 14]. Available from: <https://www.drugs.com/cosentyx.html>.
2. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Chimenti S, et al. Secukinumab in plaque psoriasis: results of a randomized, double-blind, placebo-controlled, phase 2b dose-ranging study. Br J Dermatol. 2014 Jan;170(1):128-35. doi: 10.1111/bjd.12933. Epub 2013 Aug 29. PMID: 23986212.
3. Mease PJ, McInnes IB, Kirkham B, Kivitz A, Nash P, Helliwell PS, et al. Secukinumab provides significant improvement in signs and symptoms in patients with psoriatic arthritis: results of a phase 3 randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2015 Nov;74(11):1935-42. doi: 10.1136/annrheumdis-2015-207435. Epub 2015 Aug 18. PMID: 26282112.
4. Braun J, Baraliakos X, Deodhar A, Glatt S, Kivitz A, Mease P, et al. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with ankylosing spondylitis (MEASURE 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2014 Jun 28;383(9936):239-48. doi: 10.1016/S0140-6736(14)60331-2. Epub 2014 May 21. PMID: 24849552.